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Abstract: The lung is an attractive target for drug delivery due to noninvasive administration 
via inhalation aerosols, avoidance of first-pass metabolism, direct delivery to the site of action 
for the treatment of respiratory diseases, and the availability of a huge surface area for local 
drug action and systemic absorption of drug. Colloidal carriers (ie, nanocarrier systems) in pul-
monary drug delivery offer many advantages such as the potential to achieve relatively uniform 
distribution of drug dose among the alveoli, achievement of improved solubility of the drug 
from its own aqueous solubility, a sustained drug release which consequently reduces dosing 
frequency, improves patient compliance, decreases incidence of side effects, and the potential of 
drug internalization by cells. This review focuses on the current status and explores the potential 
of colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery with special attention 
to their pharmaceutical aspects. Manufacturing processes, in vitro/in vivo evaluation methods, 
and regulatory/toxicity issues of nanomedicines in pulmonary delivery are also discussed.
Keywords: pulmonary delivery, colloidal carriers, nanocarrier systems, liposome, polymeric 
nanoparticle, solid lipid nanoparticle, submicron emulsion, dendrimer
Introduction
Burgeoning interest in colloidal carriers (nanocarrier systems) has led to increasing 
attention for pulmonary drug delivery. The lung is an attractive target for drug delivery 
due to noninvasive means to provide not only local lung effects but possibly high 
systemic bioavailability, avoidance of first-pass metabolism, more rapid onset of 
therapeutic action, and the availability of a huge surface area.1,2 Nanocarrier systems 
in pulmonary drug delivery offer many advantages. These advantages include the 
following: 1) the potential to achieve relatively uniform distribution of drug dose 
among the alveoli; 2) an achievement of enhanced solubility of the drug than its 
own aqueous solubility; 3) the sustained-release of drug which consequently reduces 
the dosing frequency; 4) suitability for delivery of macromolecules; 5) decreased 
incidence of side effects; 6) improved patient compliance; and 7) the potential of drug 
internalization by cells.3,4
Nanotechnology has been described as the manipulation, precision placement, 
measurement, modeling or manufacture of matter in the sub-100 nm range,5 although, 
depending on the context, the term sometimes identifies particles in the 1 to 200 nm 
range.3,6 However, the 100 nm limit is constraining, as in effect it would disregard 
many recent achievements and a plethora of basic science (interfacial and colloidal 
chemistry) literature and pharmaceutical research literature reports. In addition, there 
are a number of literature reports in both the basic science and pharmaceutical literature International Journal of Nanomedicine 2009:4 300
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which scientifically define dimensions of nanoparticles 
ranging in size from 1 to 1000 nm.3,7–9 In drug delivery 
systems, submicron size is significant because biodistribu-
tion of submicron particles are critical and some safety issues 
may be occurred when we use microparticles. For instance, 
after intravenous injection of parenteral formulation, large 
particles (5 µm) can cause pulmonary embolism, which 
can induce fatal results,10,11 therefore submicron particle size 
is required for parenteral formulations. Although the upper 
limit of particle size for ophthalmic application is about 5 µm, 
the optimum particle size is less than 1,000 nm because a 
scratching feeling can occur when microparticles are applied 
to the eyes.12 Phagocytosis is sensitive to particle size, and it 
is generally thought that particles of 0.5–3 µm in diameter 
are taken up by macrophages,13 and particles of less than 
0.26 µm can escape from phagocytosis by macrophages.1 
Phagocytosis is also the main mechanism responsible for 
the rapid clearance of particulate drug delivery systems from 
the body. Furthermore, cytosolic delivery of drugs can be 
achieved by endocytosis of submicron drug carriers. There-
fore, in this review, the authors consider all particulates for 
which at least one dimension is 1–1000 nm.
There are numerous applications for nanotechnology, 
however, especially the treatment, diagnosis, monitoring and 
control of biological systems have recently been referred to as 
‘‘nanomedicine’’ by the National Institutes of Health (Bethesda, 
MD, USA).14 In short, nanomedicine is the application of nano-
technology to medicine, and two main types of nanomedicine 
products are currently in clinical trials: diagnostic tests and 
drug delivery devices.15 Over the past decades, efforts have 
been focused on the development of nanomedicines such as 
nanoparticles, liposomes, nanoemulsions, or dendrimers for the 
specific delivery of drugs to the target tissues.
The modern inhalation devices can be divided into 
three different categories, nebulizers, pressurized metered 
dose inhalers (pMDI), and dry powder inhalers (DPI).1 
In most cases, nanocarriers can be delivered to the lungs by 
nebulization of colloidal dispersions or using pMDIs and 
DPIs in solid form.1,3 Due to small size and strong particle-
particle interactions of nanocarriers, particle agglomeration 
and settlement can occur in colloidal dispersions. Moreover, 
chemical instability of colloidal dispersions is another issue 
owing to carrier hydrolysis and drug degradation. To improve 
physical and chemical instability of nanocarrier dispersions, 
freeze-drying of nanocarriers has been explored as a means 
to provide a storage form. However, redispersibility and the 
use of stabilizers for lyophilization are still problematic in 
nebulization. The use of a nanocarrier itself for delivery to 
lungs is severely limited because individual nanocarriers do 
not deposit efficiently in the lungs by diffusion, sedimentation 
or impaction, which results in the exhalation of a majority 
of the inhaled dose.3 Therefore, micron-sized powder carri-
ers containing nanoparticles or agglomerated nanoparticles 
were designed to improve the inhalation aerosol delivery 
of nanoparticles for deep lung delivery by using MDIs and 
DPIs.1 A thorough discussion of incorporating nanopar-
ticles into micron-scale structures or processing methods 
for agglomerated nanoparticles are beyond the scope of 
this review, but the topic has been recently reviewed else-
where.3,4,16
This review focuses on the current status and explores 
the potential of colloidal carriers (nanocarrier systems) in 
pulmonary drug delivery with special attention to and in 
depth presentation of their pharmaceutical aspects. Manu-
facturing processes, in vitro/in vivo evaluation methods, and 
regulatory/toxicity issues of nanomedicines in pulmonary 
delivery are also presented and discussed.
Drugs for inhalation
Various drugs are investigated for local or systemic 
pulmonary delivery.2 These include small molecules, protein/
peptide drug and genes (Table 1). In case of small molecule 
drugs, many studies were focused on local application for the 
treatment of chronic respiratory diseases such as asthma and 
chronic obstructive pulmonary disease (COPD). However, 
pulmonary protein/peptide delivery offers great potential for 
both local targeting for the treatment of respiratory diseases 
and systemic targeting for the treatment of diabetes mellitus 
or thrombosis. Gene delivery to the lungs are mainly focused 
on the localized delivery of drugs to the site of disease, the 
lungs and airways, including lung cancer, genetic disorders 
affecting the airways (cystic fibrosis, alpha-1-antitrypsin defi-
ciency), obstructive lung diseases (asthma), and vaccination. 
Since original aerosol technology was developed for small 
molecule drugs, it is necessary to evolve the reengineering 
of nanocarrier self-assembly systems for macromolecular 
pulmonary delivery.17 Examples of drugs for pulmonary 
nanocarrier systems are shown in Figure 1.18–28,29–76
Nanocarrier systems for pulmonary 
drug delivery
Polymeric nanoparticulate pulmonary 
delivery
Polymeric nanoparticles are widely studied in drug 
delivery system for parenteral administration;77,78 however International Journal of Nanomedicine 2009:4 301
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Table 1 examples of drugs for pulmonary delivery using colloidal carrier self-assembly systems
Therapeutic areas and drugs Drug typesa Colloidal carrier self-assembly 
systems and referencesb
Asthma (anti-inflammatory)
  Budesonide S LP,2,3 DN4,5
  Syk antisense oligodeoxynucleotides G LP6
  Ketotifen S LP7
  Ibuprofen S DN8
  Interleukin-4 antisense oligodeoxynucleotides G PN9
  Indomethacin, ketoprofen S SLN10
  vasoactive intestinal peptide P LP,11–13 PN14
  Dexamethasone palmitate S LP15
  Fluticasone S DN5
Pulmonary hypertension
  vasoactive intestinal peptidec P LP,11–13 PN14
  vascular endothelial growth factor (veGF) gene G LP16
  Nuclear factor kB decoy oligodeoxynucleotides G NP17
  Nifedipine S DN18
Cystic fibrosis
  Amiloride hydrochloride S LP19
  Secretory leukocyte protease inhibitor P LP20
Infections
  Tobramycin S LP,21,22 DN23
  rifampicin S LP,24–27 PN,28–31 SLN32
  Isoniazid, pyrazinamide S PN,28,29 LP,27 SLN32
  Ciprofloxacin S LP33,34
  Amphotericin B S LP35,36
  Itraconazole S DN37–40
Lung cancers
  Interleukin-2 P LP41
  p53 gene G PN42–45
  9-nitrocamptothecin S LP46
  Leuprolide P LP47
  Doxorubicin S PN48
  Programmed cell death protein 4 (PDCD4) P PN49,50
  Antisense oligonucleotide 2’-O-methyl-rNA G PN51
  Akt1 (protein kinase B) sirNA G PN52,53
    6-{[2-(dimethylamino)ethyl]amino}-3-hydroxyl-7H-indeno[2,1-c] 
quinolin-7-one dihydrochloride
S PN54
Mutative defects in lung
  Chimeric oligonucleotide G PN55
Immune modulators
  Cyclosporine A P LP,56 DN57,58
  Tacrolimus S LP59
Vaccination
  HLA-A*0201-restricted T-cell epitopes from Mycobacterium tuberculosis G PN60
  v1Jns plasmid encoding antigen 85B from M. tuberculosis G Se61
Reactive oxygen species mediated diseases
  Superoxide dismutase P LP62–64
(Continued)International Journal of Nanomedicine 2009:4 302
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their application to the pulmonary routes are also widely 
recognized.4 The main roles of polymeric nanoparticles 
in drug delivery system are to carry the drug molecules, 
to protect drugs from degradation, and to control drug 
release.78 Therapeutically used polymeric nanoparticles are 
composed of biodegradable or biocompatible materials, 
such as poly(ε-caprolactone) (PCL), poly(lactic acid) 
(PLA), poly(lactic-co-glycolic acid) (PLGA), alginic acid, 
gelatin and chitosan. Various polymers for pulmonary 
drug delivery using nanocarrier systems are shown in 
Table 2. The chemical structures of polymers for polymeric 
nanoparticles used in pulmonary delivery systems are shown 
Figure 2.26,29,38,39,54–57,59,61,69,70,74,75,79–93
Due to their biocompatibility, surface modification 
capability, and sustained-release properties, polymeric 
nanoparticles are intensively studied using various impor-
tant pulmonary drugs. These pulmonary drug include anti-
asthmatic drugs,22,26 antituberculosis drugs,38,39 pulmonary 
hypertension drugs,29 and anticancer drugs.54 However, to 
avoid accumulation of polymer carriers following repeated 
dosing, the biodegradability and toxicity of polymers over 
the long term should be closely examined in the formula-
tion of polymeric nanoparticles for pulmonary delivery. 
Additionally, in vitro lung surfactant models and in vivo 
studies are required to establish the pulmonary acceptability 
of polymeric nanocarrier systems, as polymers and their 
degradation products can affect the vital surfactant properties 
in the alveoli which in turn will affect pulmonary immunity 
control and adversely affect the work of breathing.
Although cationic lipid-based gene carriers are currently 
being clinically evaluated further than polymer-based gene 
carriers,94 cationic polymers are one of the popular carriers 
for gene delivery to the lungs.95,96 Although polyethylenei-
mine (PEI) and polyamino acids, such as poly-l-lysine, have 
been shown to be effective agents for DNA delivery both 
in vitro and in vivo,97,98 cytotoxicity99 and low transfection 
efficacy problems when delivered via inhalation have to be 
overcome.100 To solve these problems, various modifica-
tions of PEI with liposomes/PEGs or conjugations of PEI 
with ligands such as transferrin have been investigated 
extensively.101–107 Noninvasive pulmonary gene delivery using 
cationic polymers has been reviewed in detail elsewhere.95
Liposomal pulmonary delivery
Liposomes are one of the most extensively investigated 
systems for controlled delivery of drug to the lung.108 
Liposomes seem particularly appropriate for therapeutic 
agent delivery to lung, since these vesicles can be prepared 
from compounds endogenous to the lungs, such as the 
components of lung surfactant, and these properties make 
liposomes attractive candidates as drug delivery vehicles.37 
The first pharmaceutical liposomal products in market 
include the synthetic lung surfactant Alveofact® (Dr Karl 
Thomae GmbH, Biberach, Germany) for pulmonary instil-
lation for the treatment of respiratory distress syndrome 
(RDS).109 Typically, liposomal formulations have been 
delivered to the lung in the liquid state, and nebulizers have 
been used extensively for the aerosol delivery of liposomes 
in the liquid state.110 However, concerns arise from drug 
stability in the liquid state and leakage when nebuliz-
ers are used to deliver a liposomal encapsulated agent.111 
Recently, liposomal dry powder formulations have been 
intensively examined in order to successfully circumvent 
these issues.72,112–114 Liposomal dry powder formulations have 
been shown to be very promising in the delivery of various 
types of pulmonary drugs and some of these formulations 
are currently in clinical trials.
Much interest has focused on cationic liposomes for 
pulmonary gene delivery because cationic liposomes offer 
the advantage of self-assembly with DNA material through 
favorable cationic–anionic electrostatic interactions. 
Additional advantages include evasion from complement 
Table 1 (Continued)
Therapeutic areas and drugs Drug typesa Colloidal carrier self-assembly 
systems and referencesb
Parathyroid disease
  elcatonin P PN65
Diabetes
  Insulin P PN,66 LP,67,68 SLN69
Thrombosis
  Low molecular weight heparin P DD70,71
  Urokinase P PN72
Notes:  aS, small molecules; P, protein/peptide; G, gene;  bDN, drug nanoparticle; PN, polymeric nanoparticle; LP, liposome; SLP, solid lipid nanoparticle; DD, dendrimer; 
Se, submicron emulsion; cCan be used for treatment of pulmonary hypertension as well as asthma.International Journal of Nanomedicine 2009:4 303
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inactivation after in vivo administration, the low cost and 
relative ease in producing nucleic acid–liposome com-
plexes in large scale.95 After first report of inhalation gene 
delivery success,115 many reports have been published 
on gene delivery using cationic liposomes by pulmonary 
administration.104,116–123 Many recent reviews95,124,125 present 
gene delivery system using cationic liposomes. Moreover, 
liposomes conjugated with cell-penetrating peptides are 
recognized as potential nanocarrier systems for intracel-
lular delivery of macromolecules to the lung. Liposomes 
modified with cell-penetrating peptides, antennapedia, 
the HIV-1 transcriptional activator, and octaarginine have 
been reported to enhance the cellular uptake of liposomes 
to airway cells.126
Solid lipid nanoparticles in pulmonary 
delivery
Solid lipid nanoparticles (SLNs) are made from solid 
lipids (ie, lipids solid at room temperature), surfactant(s) 
and water.127 Since the beginning of 1990s, the SLNs have 
been focused on an alternative to polymeric nanopar-
ticles.109 The advantages of drug release from SLNs in the 
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lung are control of the release profile, achievement of a 
prolonged release and having a faster in vivo degradation 
compared to particles made from PLA or PLGA. In addi-
tion, SLNs proved to possess a higher tolerability in the 
lungs compared to particles made from some polymeric 
materials.109,128,129 Although SLNs for the pulmonary 
delivery is not fully appreciated, toxicological profile of 
SLNs, when using physiological lipids, is expected to be 
better than that of polymer-based systems, because physi-
ological lipids have little or no cytotoxicicity.130,131 It is 
feasible that aqueous suspensions and perhaps dry powder 
formulations of SLN can be used for pulmonary inhalation 
Table 2 various polymers for colloidal pulmonary drug delivery systems
Polymers Drugs and references Size
Alginate
  Sodium alginate rifampicin, isoniazid, pyrazinamide29 235.5 nm
Chitosan
  Chitosan Plasmid DNA77 91–164 nm
Small interfering rNA78 40–600 nm
  Chitosan/tripolyphosphate Insulin79 300–388 nm
  Trisaccharide-substituted chitosan Plasmid DNA80 77–90 nm
  Urocanic acid–modified chitosan Programmed cell death protein 450 NA
Gelatin
  Gelatin type A Fuoresceinamine81 277.8 nm
  Gelatin type B Sulforhodamine 101 acid chloride82 242 ± 14 nm
  PeGylated gelatin Plasmid DNA83 100–500 nm
Polyalkylcyanoacrylate
  Polybutylcyanoacrylate Insulin66 254.7 nm
Doxorubicin84 173 ± 43 nm
Ciprofloxacin85 156–259 nm
PLGA
  PLGA rifampicin, isoniazid, pyrazinamide28 570–680 nm
  PeG-PLGA Nuclear factor κB decoy oligodeoxynucleotide17 44 nm
  Chitosan-modified PLGA elcatonin65 650 nm
  Chitosan/PLGA Antisense oligonucleotide 2-O-methyl-rNA51 135–175 nm
    Poly[vinyl 3-(diethylamino)propylcarbamate-co-vinyl 
acetate-covinyl alcohol]-graft-PLGA
5(6)-carboxyfluorescein86 195.3 ± 7.1 nm
Proticle
  Protamine-oligonucleotide vasoactive intestinal peptide14 177–318 nm
PEI
  PeI Chimeric oligonucleotide55 30–100 nm
Plasmid DNA87 50–100 nm
  PeI-alt-PeG Small interfering rNA53 NA
  Glucosylated PeI Programmed cell death protein 449 NA
  Galactose-PeG-PeI Plasmid DNA88 105–210 nm
  Cell-penetrating peptides-PeG-PeI Plasmid DNA89 113–296 nm
Poly-L-lysine
  PeGylated poly-l-lysine Plasmid DNA90,91 211 ± 29 nm
Dendrimer
  G9 PAMAM Plasmid DNA92 NA
  G2/G3 PAMAM Low molecular weight heparin70 NA
  Pegylated G3 PAMAM Low molecular weight heparin71 17.1 ± 3.3 nm
Abbreviations: PeG, poly(ethylene glycol); PLGA, poly(lactic-co-glycolic acid); PeI, poly(ethylenimine); PAMAM, polyamidoamine; NA, not available.International Journal of Nanomedicine 2009:4 305
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aerosol administration of drugs using nebulizers and dry 
powder inhalers.109
Several studies have been published on the pulmonary 
applications of SLNs as local delivery carriers for 
small molecules42 or as systemic delivery carriers for 
macromolecules.73,132 Pandey and Khuller42 studied the 
chemotherapeutic potential of SLNs incorporating rifam-
picin, isoniazid and pyrazinamide against experimental 
tuberculosis, and observed the slow and sustained-release 
of drugs from the SLNs in vitro and in vivo. Gene delivery 
Figure 2 Chemical structures of polymers for polymeric nanoparticles in pulmonary delivery systems.
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of SLN-based gene vectors was introduced by Rudolph and 
colleagues.132 They reported that SLN gene vectors mediate 
gene expression in the mouse lungs upon aerosol application, 
which was increased by the TAT peptide, and aerosol 
application of fragile gene delivery systems can be achieved 
by a mild nebulization technology based on a novel perforated 
membrane technology. Liu and colleagues73 studied novel 
nebulizer-compatible SLNs containing insulin for pulmonary 
delivery. They concluded that SLNs could be successfully 
applied as a pulmonary carrier system for insulin, which 
might provide novel solutions to the currently unmet medical 
needs for systemic delivery of proteins.
Deposition and clearance of SLNs were assessed by 
Videira and colleagues133,134 after inhalation of aerosolized 
insoluble particles using gamma-scintigraphy imaging 
analysis. It was observed that a few minutes after deposi-
tion, inhaled material began to translocate to regional lymph 
nodes indicating that inhalation can be an effective route 
to deliver drug-containing lipid partices to the lymphatic 
systems and lipid particles can be used as potential drug 
carriers for lung cancer therapy, as well as for vaccine 
delivery.133,134
Submicron emulsions in pulmonary 
delivery
Until now, the submicron emulsion system has not yet 
been fully exploited for pulmonary drug delivery and very 
little has been published in this area.65 Cationic submicron 
emulsion loaded with Mycobacterium tuberculosis Ag85B 
DNA vaccine was explored vaccine for the purpose of 
pulmonary mucosal vaccination.65 Emulsion systems 
have been introduced as alternative gene transfer vectors 
to liposomes.135 Other emulsion studies for gene delivery 
(nonpulmonary route) have shown that binding of the 
emulsion/DNA complex was stronger than liposomal 
carriers.136 This stable emulsion system delivered genes to 
endothelial cells in the mouse nasal cavity more efficiently 
than commercially available liposomes.137 Bivas-Benita 
and colleagues65 have reported that cationic submicron 
emulsions are promising carriers for DNA vaccines 
to the lung since they are able to transfect pulmonary 
epithelial cells, which possibly induce cross priming of 
antigen-presenting cells and directly activate dendritic 
cells, resulting in stimulation of antigen-specific T-cells. 
Therefore the nebulization of submicron emulsions will 
be a new and upcoming research area. However, exten-
sive studies are required for the successful formulation of 
inhalable submicron emulsions due to possible adverse 
effects of surfactants and oils on lung alveoli function 
(adverse interactions with lung surfactant).
Dendrimer-based nanoparticles for lung 
delivery
Dendrimers are polymers, which have hyperbranched 
structures, with layered architectures.138 The research in 
dendrimer-mediated drug delivery has mainly been focused 
on the delivery of DNA drugs into the cell nucleus for gene 
or antisense therapy, and many studies have been reported 
on the possible use of dendrimers as nonviral gene transfer 
agents.138 Several studies have been published regarding 
pulmonary applications of dendrimers as systemic delivery 
carriers for macromolecules.74,75,93,139
Kukowska-Latallo and colleagues93 investigated the 
ability of polyamido amine (PAMAM) dendritic polymers 
(dendrimers) to augment plasmid DNA gene transfer in vivo 
and evaluates the targeting of the lung by alternative routes 
of administration. They suggested that vascular administra-
tion seemed to achieve expression in the lung parenchyma, 
mainly within the alveoli, while endobronchial administration 
primarily targeted bronchial epithelium, indicating that each 
delivery route requires different vectors to achieve optimal 
transgene expression, that each approach appears to target 
different cells within the lung.
Rudolph and colleagues139 compared the properties of 
branched polyethylenimine (PEI) 25 kDa and fractured 
PAMAM dendrimers for topical gene transfer to the air-
ways in vivo. Their results demonstrated that gene transfer 
mediated by PEI under optimal conditions was two orders 
of magnitude higher compared to fractured dendrimers. 
Therefore, branched PEI 25 kDa was superior to fractured 
dendrimers for gene delivery to the airways.
Bai and colleagues74 produced low molecular weight 
heparin (LMWH)–dendrimer complex through electrostatic 
interactions using various PAMAM dendrimers, then evalu-
ated both the safety and the efficacy of the drug–dendrimer 
formulations in preventing deep vein thrombosis in vivo 
and in situ. They concluded that cationic dendrimers can 
be used as pulmonary delivery carriers for a relatively large 
molecular weight anionic drug. These carriers bind anionic 
drug molecules most likely via electrostatic interactions and 
increase drug absorption through charge neutralization. In 
addition, preliminary safety studies using the frog palate 
model and bronchoalveolar lavage analysis suggest that 
dendrimers could be viable carriers for pulmonary delivery 
of LMWH. In another study the same group75 also inves-
tigated pegylated dendrimers (mPEG–dendrimer) in order International Journal of Nanomedicine 2009:4 307
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to increase pulmonary absorption and circulation time 
of the drug. Brieﬂy, half-life and absorption of LMWH 
administered via the pulmonary route can be increased by 
encapsulating the drug in dendrimeric micelles, and their 
study suggests that LMWH loaded in the mPEG–dendrimer 
could potentially be used as noninvasive delivery system 
for the treatment of thromboembolic disorder. However, the 
potential of dendrimers in the pulmonary drug administration 
route still remains as a challenge that needs further research 
to achieve lower cytotoxicity and higher biocompatibility.
Manufacture of nanoparticulate 
inhalation aerosols
In formulation preparation, several processing technologies 
have been used to obtain nanoparticles for use as pulmonary 
inhalation aerosols with desirable attributes, such as narrow 
particle size distribution, enhanced stability, controlled and 
targeted release, and improved bioavailability. Jet-milling of 
the drug under nitrogen gas is the traditional way of creating 
respirable aerosol particles in the solid-state.140,141 The basic 
procedure of jet-milling is to grind a bulk crystallized par-
ticles into small particles by one of the following mechanical 
forces: pressure, friction, attrition, impact, or shear. However, 
up until very recently, this technology had a limitation to 
generate particles in the nanosized range, although a few 
cases have been reported to produce nanoparticles, such as 
insulin nanoparticles142 and budesonide nanoparticles,143 by 
wet milling process. The recent availability of new nanojet 
milling instruments which produce nanoparticles by jet 
milling may increase the routine use of creating nanoparticles 
by this method.
More sophisticated and advanced manufacturing 
technologies are utilized to produce respirable aerosol 
nanoparticles. These respirable particles may be encapsu-
lated in microparticles in the respirable aerodynamice size 
range of 1–5 microns or the nanoparticles may be designed 
to aggregate to a favorable aerodynamic size range. These 
manufacturing nanotechnologies include spray drying (some-
times referred to as advanced spray drying or nanospray 
drying), spray-freeze drying, supercritical ﬂuid technology, 
double emulsion/solvent evaporation technology, antisolvent 
precipitation, particle replication in nonwetting templates 
(PRINT), and thermal condensation using capillary aerosol 
generator.
Spray-drying
Spray-drying is an advanced pharmaceutical manufacturing 
process used to efficiently produce respirable colloidal 
particles in the solid-state.144,145 In the process, the feed 
solution is supplied at room temperature and pumped to the 
nozzle where it is atomized by the nozzle gas. The atomized 
solution is then dried by preheated drying gas in a special 
chamber to remove water moisture from the system, thus 
forming dry particles. These prepared particles are collected 
with a cyclone separation device. A schematic representation 
of a spray drying process is shown in Figure 3.
The spray-drying process is suitable for thermolabile 
materials such as proteins and peptides, because mechanical 
high energy input is avoided in this process.146–148 Moreover, 
the spray-drying system can be modified to meet specific 
needs. For example, Maa and colleagues149 replaced the 
bag-filter unit of a spray-drying system with a vacuum to 
reduce the drying airﬂow resistance. It allows the protein 
(recombinant humanized anti-lgE antibody) to be dried at a 
much lower temperature than usual and the production scale 
to be increased.146 In another study, poly(lactic-co-glycolic 
acid) particles containing proteins were successfully dried by 
ultrasonic atomization of feed solution into an atmosphere 
under reduced pressure.147 Solution spray-drying ensures 
compositional homogeneity of the drug powder, since the 
drug and the excipients are dissolved prior to the process. 
More importantly, spray-drying can result in uniform particle 
morphology.114,149,150 In industry, spray-drying is a continu-
ous production method, scalable for commercial production 
volumes.
Lactose monohydrate is the only US Food and Drug 
Administration (FDA)-approved sugar carrier for dry pow-
der aerosol formulations and one of a few FDA approved 
excipients.151 For example, lactose with either gelatin or 
poly(butylcyanoacrylate) nanoparticles were spray dried to 
produce particles for pulmonary delivery.84 Lactose in solid 
form can be either crystalline as lactose monohydrate or 
amorphous as lactose. Crystalline lactose can exist in one of 
two distinct forms: α-lactose monohydrate (Figure 4a) and 
anhydrous β-lactose (Figure 4b). Amorphous lactose may 
contain both α- and β-lactose molecules that are arranged 
in a more or less random state. α-lactose monohydrate and 
anhydrous β-lactose are superior in offering better physical 
stability than amorphous lactose as the later has a tendency 
to recrystallize spontaneously.152,153 A disadvantage of lactose 
monohydrate, a reducing sugar, as a sugar carrier and/or 
excipient in the solid-state is that it participates in Maillard 
decomposition reactions with certain small molecular weight 
pulmonary drugs (eg, budesonide, formoterol), proteins 
and peptides.154 Recently, D-mannitol, a nonreducing sugar 
alcohol, whose molecular structure is shown in Figure 4c, has International Journal of Nanomedicine 2009:4 308
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been used as an alternative sugar carrier of pulmonary drugs 
in dry powder inhalation aerosols, since it does not participate 
in the solid-state decomposition Maillard reaction.155
Spray-freeze-drying (SFD)
Spray-freeze-drying (SFD) is an advanced particle 
engineering method which combines spray-drying and 
freeze-drying processing steps. This technique involves 
the atomization of an aqueous drug solution into a spray 
chamber filled with a cryogenic liquid (liquid nitrogen) 
or halocarbon refrigerant such as chloroﬂuorocarbon or 
ﬂuorocarbon.156 The water is removed by sublimation after 
the liquid droplets solidify.157 SFD is capable of producing 
porous particles with high fine particle fraction (FPF) at 
subambient temperatures.157 They are usually low-density 
composite amorphous particles with high specific surface 
area.158 Thermolabile protein and peptide substances, such 
as insulin159 and plasmid DNA,160 can also be formulated into 
dry powder inhalation products by SFD.
Supercritical fluid technology (SCF)
The basic feature of the supercritical ﬂuid process is the 
controlled crystallization of drugs from dispersion in super-
critical ﬂuids, carbon dioxide. This method has demon-
strated a wide range of application in producing pulmonary 
inhalable formulations.23,161,162 Supercritical ﬂuid technology 
can be divided into several classes. The most important two 
are supercritical antisolvent precipitation (SAS)163,164 and 
supercritical ﬂuid extraction of emulsions (SFEE).165,166 
The fundamental mechanism of SAS is based on rapid 
precipitation when a drug solution is brought into contact 
with a supercritical CO2. SFEE is based on extraction of 
the organic phase in oil-in-water or multiple emulsions 
using supercritical CO2.165,166 The schematic representation 
of SAS and SFEE processes is shown in Figure 5. Because 
most of the drugs (eg, asthma drugs) are not soluble in 
CO2, SAS processes provide an easy and excellent way 
to produce dry powder inhalation formulations.163,164 
SFEE can provide uniform crystalline drug nanoparticles, 
composite nanoparticles containing polymeric materials 
and the drugs, and nanosuspensions.165,166 For instance, 
Chattopadhyay and colleagues23 used a continuous SFEE 
method to produce nanoparticle suspensions containing one 
of three lipids (tripalmitin, tristearin, or gelucire 50/13), 
and one of two model drugs (indomethacin or ketoprofen). 
The first step of this process was to produce nanoemulsions 
by mixing organic phase containing lipids, a selected drug 
and chloroform with aqueous phase containing sodium gly-
cocholate, under high pressure homogenization. Then the 
nanoemulsions were introduced to an extraction chamber 
countercurrently to a stream of supercritical CO2. The CO2 
extracted the organic solvent from the dispersed droplets, 
Figure 3 A schematic representation of the spray-drying process.
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forming nanoparticles with a volume mean diameter 
between 10–30 nm with a high drug loading efficiency for 
the gelucire particles (∼80%–90%). In another example, 
nanoparticles containing cholesterol acetate (CA), griseo-
fulvin (GF), and megestrol acetate (MA) were produced by 
extraction of the internal phase of oil-in-water emulsions 
using supercritical carbon dioxide.165 This method offered 
advantages such as the control of particle size, crystallinity, 
and surface properties. Meanwhile, it shortened the pro-
cessing time, improved the product purity, and reduced the 
large waste streams.
Double emulsion/solvent evaporation 
technique
Respiratory nanoparticle formation from double emulsion/
solvent evaporation system involves preparation of oil/water 
(o/w) emulsions with subsequent removal of the oil phase 
(ie, typically a volatile organic solvent) through evapora-
tion. The emulsions are usually prepared by emulsifying 
the organic phase containing the drug, polymer and organic 
solvent in an aqueous solution containing emulsifier. The 
organic solvent diffuses out of the polymer phase and into the 
aqueous phase, and is then evaporated, forming drug-loaded 
polymeric nanoparticles. By this method, biodegradable 
polymers, including poly(l-lactic acid) (PLA), poly(glycolic) 
acid (PGA), and poly(lactide-co-glycolide) acid (PLGA), 
have been intensively investigated as carriers for solid drug 
nanoparticles.167
Antisolvent precipitation
Crystalline drug particles with narrow size distribution 
could be prepared by direct controlled crystallization.168 This 
process involves antisolvent precipitation of drug solution in 
a water-miscible organic solvent, followed by addition of a 
bridging solvent, which is immiscible or partially miscible 
with water. Growth-retarding stabilizing additives, such as 
hydroxylpropylmethylcellulose (HPMC), is usually added in 
the medium to yield particles with small size. The precipi-
tated drug crystals exhibit a high FPF and low amorphous 
content.169
Particle replication in nonwetting 
templates (PrINT)
PRINT is a top-down particle fabrication technique devel-
oped by Dr. Joseph DeSimone and his group. This tech-
nique is able to generate uniform populations of organic 
micro- and nanoparticles with complete control of size, 
shape and surface functionality, and permits the loading 
of delicate cargos such as small organic therapeutics, pep-
tides, proteins, oligonucleotides, siRNA, contrast agents, 
radiotracers, and ﬂuorophores.170–172 All these features are 
essential for controlling in vivo transport, biodistribution, 
Figure 4 Molecular structures of sugar carriers: A) α-lactose monohydrate, B) anhydrous β-lactose and C) D-mannitol.
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and drug-release mechanisms of nanoparticles. The principle 
of PRINT is to utilize a low surface energy ﬂuoropolymeric 
mold that enables high-resolution imprint lithography, an 
emerging technique from the microelectronics industry, to 
fabricate a variety of organic particles. PRINT is therefore 
an adaptation of lithographic techniques found in the micro-
electronics industry to fabricate carriers of precise size for 
use in nanomedicine. Through the use of an appropriately 
designed master template, PRINT can precisely manipulate 
particle size ranging from 20 nm to more than 100 µm. The 
shape of particles can be sphere, cylinder, discs, and toroid 
with defined aspect ratios. PRINT is a promising and novel 
technology in nanoparticulate design and manufacture for 
use in pulmonary delivery.
Thermal condensation aerosols
Thermal condensation is a cutting edge technology which 
uses capillary aerosol generator (CAG) to produce high 
concentration condensation submicron to micron sized 
aerosols from drug solutions. The drug solution is pumped 
through a heated capillary tube. Precisely controlled heating 
of the capillary causes the solution to evaporate. Formula-
tion vapor exiting the tip of the capillary tube mixes with the 
cooler surrounding air, and then becomes supersaturated and 
initiates nucleation. The condensation of surrounding vapor 
onto the generated nuclei results in an aerosol. Various drugs, 
such as perphenazine,173 prochlorperazine,174 rizatriptan175 
and benzyl,176 have been aerosolized using this technique. 
Propylene glycol (PG) is a popular solvent chosen to dissolve 
the drugs.177 However, in some cases, rapid heating of thin 
films of pharmaceutical compounds can also vaporize the 
molecules, leading to formation of aerosol particles of 
optimal size for pulmonary drug delivery.178 By controlling 
the film thickness, the purity of aerosols can be enhanced by 
reducing the amount of aerosol decomposition.179
In vitro evaluation methods 
for pulmonary drug delivery systems
In vitro characterization of 
nanoparticulate aerosol systems
Nanoparticles for pulmonary drug delivery can be evaluated 
by comprehensive characterization methods. Table 3 lists 
several important techniques as well as their functions in the 
in vitro characterization study of the behavior of nanopar-
ticulate pulmonary inhalation aerosols.180
Inertial impaction is the standard method to measure the 
particle or droplet aerodynamic size from pharmaceutical 
aerosol delivery systems.181,182 It describes the phenomenon 
of the deposition of aerosol particles on the walls of an airway 
conduct. The impaction (obstruction) tends to occur where 
the airway direction changes. The big particles have high 
momentum (inertia) and are more likely to travel in the initial 
direction of airﬂow, while those with low momentum adjust 
to the new direction of ﬂow and pass around the obstruction. 
Inertial impaction employs Stokes’ law to determine the 
aerodynamic diameter of particles being evaluated. This has 
the advantage of incorporating shape and density effects into 
a single term.141
In addition to the conventional commercially avail-
able cascade impactors, MSP Corporation (Minneapolis, 
MN, USA) has recently developed a new commercially 
available nanomicroorifice uniform deposition impactor 
(Nano-MOUDI™) device with high accuracy in sampling 
and collecting size-fractionated airborne particle samples 
and pharmaceutical aerosol particle samples for gravimetric 
and/or chemical analysis. The Nano-MOUDI™ differs from 
conventional cascade impactors by using microorifice nozzles 
to reduce the jet velocity, pressure drop, particle bounce, and 
evaporative loss. These impactors also have a uniform deposit 
feature by rotating the impaction plates with respect to the 
Table 3 Methods to characterize the physicochemical and aerodynamic properties of particles (microparticles and nanoparticles) for 
pulmonary inhalation delivery
Technology Function
Inertial impaction Measurement of the aerodynamic size of particles
XrPD Measurement of molecular long-range vs short-range order
DSC Measurement the phase transitions and phase behavior
SeM visualization of the surface morphology of particles
AFM Surface nanotopographical imaging, surface free energy measurements, and measure of interparticulate forces
IGC Determination of the surface free energy of bulk powders
Karl Fisher titration Analytical quantification of water content in pharmaceutical powders, liquids, and semi-solids
Abbreviations: AFM, atomic force microscopy; DSC, differential scanning calorimetry; IGC, indocyanine green; SeM, scanning electron microscopy; XrPD, X-ray particle 
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nozzles to spread out the particle deposit uniformly on the 
collection substrates. The uniform deposit prevents heavy 
particles build-up under each nozzle to reduce particle bounce 
and blow-off that may otherwise occur. Nano-MOUDI™ is 
also superior to conventional cascade impactors in its aero-
dynamic design features. It is designed to prevent cross-ﬂow 
interference between adjacent nozzles, which results in sharp 
cut-size characteristics not available with other cascade 
impactors. Because of its superior aerodynamic design and 
outstanding performance characteristics, Nano-MOUDI™ 
has an increasing application in environmental air quality 
and air pollution studies.183–190 We believe its application in 
pharmaceutical nanoaerosol drug delivery characterization 
and modeling is very promising, as well.
X-ray powder diffraction (XRPD) is one of the most 
important characterization tools used in solid state chem-
istry and materials science, since it directly measures 
the degree of molecular long-range vs short-range order. 
Molecular long-range order is indicative of crystallinity, 
while short-range order is indicative of noncrystallinity such 
as liquid crystallinity and amorphicity. It gives information 
about the extent and nature of crystallinity and molecular 
order for solid-state materials, ie, how the atoms pack 
together in the crystalline state and what the interatomic 
distance and angle are.191–194
Differential scanning calorimetry (DSC) is a powerful 
and routinely used pharmaceutical thermal analytical method 
for phase behavior study on polymorphs, hydrates, binding 
interactions, amorphocity, thermotropic and lyotropic phase 
transitions of pharmaceutical materials, including nanopar-
ticles. DSC directly measures the gain and loss of enthalpy, 
that is, order-to-disorder (eg, melting) and disorder-to-order 
(eg, crystallization) phase transitions.195
Scanning electron microscopy (SEM) is used to visualize 
the surface morphology of particles with a high magnifica-
tion. The resolution allows identification of specific surface 
features and asperities that lead to mechanical interlocking 
(ie, structural cohesion) and that contain high-energy “active” 
Figure 5 Schematic representations of A) SAS and B) SFee processes.
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sites on the surface which influence surface energetic 
properties and interparticulate interactions and ultimately 
inﬂuence aerosol dispersion performance.180 Surface and 
interfacial/interparticulate forces are of great importance 
in the properties of nanoparticles and in the properties of 
aerosols. Atomic force microscopy (AFM) is used in surface 
nanotopographical imaging, measurement of surface energy, 
and measurement of interparticulate forces. This microscopy 
works in mesoscopic scale resolution (10-6–10-9 m).196 
Inverse gas chromatography (IGC) measures the surface 
free energy of bulk powders such as polymers, fibers, and 
composite materials.197
Karl Fischer titration is used to analytically quantify 
small amounts of water present in the inhalation powder 
which has important consequences on capillary condensa-
tion (ie, capillary force is an important interparticulate force 
in inhalation aerosol particles), solid-state phase behavior, 
solid-state properties, and solid-state stability of pharmaceuti-
cal particles in the solid-state.198
In vitro pulmonary cell culture models
The lung can be anatomically divided into several parts: 
the trachea, the main bronchi, the conducting bronchioles, 
the terminal bronchioles and the alveoli.199,200 Drug delivery 
via inhalation may be absorbed throughout the conducting 
airway from the trachea down to the terminal bronchioles 
and ultimately the distal alveoli.201 The airway and alveolar 
epithelium of the lung, which have different cell types, 
provide barrier capability to drug absorption.
In order to better understand the drug absorption process 
in different regions (eg, tracheal, bronchial and alveolar) of 
the respirable barriers, in vitro pulmonary cell culture models 
have been developed.201–205 The cell lines used include A427, 
A549, HBE14o, and the Calu line (-1, -2, and -3).205–210 These 
are immortal (continuous) cell lines and hence have different 
membrane structural features compared with mortal cell lines 
which inﬂuence drug absorption and efﬂux. For example, 
A549 cell line represents the alveolar type II pulmonary 
epithelial cell, and has been reported to be an ideal model 
to study the metabolic and macromolecule mechanisms of 
drug delivery at the alveolar pulmonary epithelium because 
the endocytic ability of the pulmonary epithelium and local-
ization of cytochrome P450 systems is largely a function 
of type II pneumocytes.209 Calu-3 and HBE14o model the 
upper airways (bronchi) and many studies have been con-
ducted on them. For example, the permeability data of small 
lipophilic molecule (eg, testosterone) and high molecular 
weight substance (eg, ﬂuorescein isothiocyanate-transferrin) 
across Calu-3 cell line has been examined by Foster and 
colleagues.208 The authors demonstrated this cell line is 
useful for studying the contributions of bronchial epithelial 
cells to the mechanisms of drug delivery at the respiratory 
epithelium. Similar conclusions were drawn when the appar-
ent permeability of the glucocorticosteroid budesonide was 
investigated.206
Primary cultured cells have also been used in pulmonary 
absorption and transport studies. These cell cultures have 
advantages over continuous cells by exhibiting tight junc-
tions. It is important for cell cultures to form a sufficient and 
appropriately tight polarized monolayer, so that the transport 
kinetics of test molecules can be properly assessed.211
In vivo evaluation methods 
for pulmonary drug delivery systems
Pharmacokinetic study after nebulization 
of colloidal dispersion of drugs
Colloidal drug dispersions have been delivered to male ICR 
mice via nebulization using a restraint-free small animal 
inhalation dosing chamber. Then, the mice were sacrificed at 
pre-determined time points post-dosing. Blood samples were 
taken by cardiac puncture, and the lungs were harvested for 
analysis by analytical instrument. From these experiments, 
lung and serum (blood) pharmacokinetics of colloidal drug 
dispersions can be determined as reported previously.212–214
Biodistribution study using radiolabeled 
SLNs
To assess the inhaled radiolabelled SLNs biodistribution, 
nanoparticles (200 nm) were radiolabeled with  99mTc and 
biodistribution studies were carried out following aerosolisa-
tion and administration of a 99mTc-HMPAO-SLNs suspension 
to a group of adult male Wistar rats. After administration 
of radiolabeled SLNs, dynamic image acquisition was 
performed in a gamma-camera, followed by static image 
collection. Then radiation counting was performed in organ 
samples, collected after the animals were sacrificed. From 
these experiments, biodistribution of SLNs can be traced 
and evaluated.133,134
Fluorescence/bioluminescence imaging 
systems for pulmonary gene delivery
Visualization and evaluation of both the pulmonary delivery 
and the gene expression properties after dry powder 
inhalation in mice were recently reported by Mizuno and 
colleagues.215 It was shown that the pulmonary delivery and International Journal of Nanomedicine 2009:4 313
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the gene expression can be evaluated using ﬂuorescence 
of indocyanine green (ICG) as a ﬂuorescent label and the 
detection of luciferase activity, respectively, by using a non-
destructive real-time in vivo imaging system. They concluded 
that the dry powder containing both ICG and pCMV-Luc 
was useful as a dual imaging system to visualize pulmonary 
delivery and gene expression in mice.
Regulatory and toxicity issues
Inhaled microparticles and nanoparticles of different sizes 
can target into different regions of respiratory tract, including 
nasopharyngeal, tracheal, bronchial, and alveolar regions, 
with several mechanisms. Meanwhile, the surface chemistry, 
charge, shape and aggregation status of nanoparticles 
also have inﬂuences on their disposition efficacy.216 For 
example, inhaled large particles and nanoparticles deposit 
in the respiratory tract by distinctive mechanisms. Large 
particles deposit via inertial impaction, gravitation settling 
and interception mechanisms, while nanoparticles deposits 
via diffusion due to displacement when they collide with air 
molecules. The presence of albumin217 and phospholipids 
(eg, lecithin)218 in alveolar epithelial lining ﬂuid is important 
to facilitate epithelial cell uptake of nanoparticles after 
deposition in the alveolar space. Nanoparticles coated 
with them may translocate across the alveolo–capilliary 
barrier, whereas uncoated particles do not. Therefore, 
when evaluating the efficacy and fate of nanoparticles by 
inhalation delivery, all the variables should be taken into 
consideration.1
After delivery into the lung, some nanoparticles may be 
translocated to extrapulmonary sites and reach other target 
organs by cellular endocytosis, transcytosis, neuronal,219 
epithelial220 and circulatory221 translocation and distribu-
tion, which makes them desirable for medical therapeutic 
or diagnostic application. However, these features can also 
pose potential toxicity. Transcytosis absorbs nanoparticles 
and translocate them into the interstitial sites, where they 
gain access to the blood circulation via lymphatics, resulting 
in distribution throughout the body. Neuronal translocation 
involves uptake of nanoparticles by sensory nerve endings 
embedded in airway epithelia, followed by axonal transloca-
tion to ganglionic and central nerve systems (CNS) structures. 
For example, nanoparticles facilitating drug delivery to the 
CNS in the brain raises the question of fate of nanopar-
ticles after their translocation to the specific cell types or 
to subcellular structures. This kind of questions includes 
whether mitochondrial localization induces oxidative stress 
and how persistent the coating or the core of nanoparticles 
is, which is essential in nanoparticle toxicology and safety 
evaluation.222
The clearance of nanoparticles in the alveolar region is 
predominantly mediated by alveolar macrophages, through 
phagocytosis of deposited nanoparticles. After macrophages 
recognize the deposited nanoparticles and phagocytize them, 
macrophages with internalized nanoparticles gradually move 
toward the mucociliary escalator, and then the clearance 
process is started. The retention half-time of solid particles 
in the alveolar region based on this mechanism is very 
slow, up to 700 days in humans. Moreover, unlike larger 
particles, results from several studies show the apparent inef-
ficiency of alveolar macrophage phagocytosis of nanosized 
particles.223–225 The ultrafine nanoparticles are not easily 
phagocytized by macrophages and, consequently, are not 
readily cleared in the alveolar region.226 These nanoparticles 
are either in epithelium cells or are further translocated to 
the interstitium, which may cause a long-term accumulation 
in the lung and subsequent toxicity issues.
According to the FDA guidance for dry powder inhaler 
(DPI) drug products, α-lactose monohydrate is the only 
approved sugar that can be used as a large carrier particle 
in dry powder inhalation aerosol products to ﬂuidize and 
disperse the respiratory drug while itself not being delivered 
to the lung. Other novel materials, including phospholipids, 
specifically lecithin and amino acids (lysine, polylysine) have 
also been developed for use in pulmonary formulations as 
excipients that are delivered to the lung. A thorough assess-
ment of these alternatives associated with any inhalable 
substance is required, from a variety of sources: human, 
animal, and/or in vitro test models.227
Conclusions
Inhalable colloidal carriers (nanocarrier systems) offer 
numerous advantages. The decrease in particle size leads 
to an increase in surface area leading to enhanced dis-
solution rate, as well as relatively uniform distribution of 
drug dose among the alveoli. In addition, by suspending 
the drugs in nanoparticles, one can achieve a dose that is 
higher than that offered by a pure aqueous solution, which 
is thermodynamically limited by the aqueous solubility of 
the drug. Nanocarrier systems can provide the advantage 
of sustained-release in the lung tissue, resulting in reduced 
dosing frequency and improved patient compliance. Local 
delivery of inhalable nanocarriers may be a promising alter-
native to oral or intravenous administration, thus decreasing 
the incidence of side effects associated with a high drug 
serum concentration. As with all formulations designed for International Journal of Nanomedicine 2009:4 314
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pulmonary drug delivery, the potential long-term risk of 
excipient toxicity and nanoscale carrier itself are issues that 
need to be considered in the successful product development 
of pulmonary drug delivery systems. Nevertheless, their 
inherently small size and surface modification properties 
enable further opportunities for innovative controlled drug 
release and pulmonary cell targeting therapeutic platforms. 
The integration of nanotechnology and pulmonary delivery 
has the potential to improve the targeting, release, and thera-
peutic effects of drugs and needle-free inhalation vaccines 
with significant potential capability of overcoming the 
physicochemical and biological hurdles.
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